BACKGROUND: The dose of oral anticoagulants (OAC) shows great variability among @entity1 . Pharmacogenetic studies have shown that common variants in genes @entity5060 (*2 and *3) and @entity5058 ( @entity30883 ) are associated with lower requirements of OAC. AIM: To study the association between average maintenance doses of oral anticoagulant therapy required to maintain a stable INR and @entity5060 and @entity5058 gene variants in Chilean adults. MATERIAL AND METHODS: Prospective study of patients on anticoagulant treatment and with a stable international normalized ratio (INR) for prothrombin time for at least three months. @entity1 were classified as having high or low @entity11271 or @entity1229 requirements. Peripheral blood DNA genotyping was performed by polymerase chain reaction and restriction fragment polymorphism or sequencing and electrophoresis. RESULTS: The study included 185 @entity1 , 125 on @entity11271 and 60 on @entity1229 . @entity1 with @entity5058 -1639A allele were more likely to require lower doses of both drugs than @entity1 with the G allele (Odds ratio [OR] for @entity11271 9.06, and OR for @entity1229 = 18.7). There was no association between @entity5060 *2 and*3 and @entity11271 or @entity1229 requirements. CONCLUSIONS: There is an association between @entity5058 -1639A variant and anticoagulant doses.

[Effect of XXXX and @entity5060 variants on dosage of oral anticoagulants in Chilean individuals].

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity11271 :: ('MESH:D000074', 'Chemical') :: ['acenocoumarol'] @entity5058 :: ('79001', 'Gene') :: ['VKORC1'] @entity30883 :: ('c|SUB|G|-1639|A', 'DNAMutation') :: ['-1639G>A'] @entity5060 :: ('1559', 'Gene') :: ['CYP2C9'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']
@entity5058 :: (79001,Gene) :: ['VKORC1']
